KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares RepurchasedShort-Term Debt repayments
Ratios

Pacira BioSciences (PCRX) Other Gross PP&E Adjustments (2016 - 2025)

Pacira BioSciences (PCRX) has 15 years of Other Gross PP&E Adjustments data on record, last reported at $236.6 million in Q4 2025.

  • For Q4 2025, Other Gross PP&E Adjustments fell 5.68% year-over-year to $236.6 million; the TTM value through Dec 2025 reached $236.6 million, down 5.68%, while the annual FY2025 figure was $236.6 million, 5.68% down from the prior year.
  • Other Gross PP&E Adjustments reached $236.6 million in Q4 2025 per PCRX's latest filing, up from $221.5 million in the prior quarter.
  • Across five years, Other Gross PP&E Adjustments topped out at $250.9 million in Q4 2024 and bottomed at $147.3 million in Q1 2021.
  • Average Other Gross PP&E Adjustments over 5 years is $206.9 million, with a median of $211.9 million recorded in 2022.
  • Peak YoY movement for Other Gross PP&E Adjustments: soared 43.77% in 2021, then fell 5.68% in 2025.
  • A 5-year view of Other Gross PP&E Adjustments shows it stood at $197.2 million in 2021, then rose by 16.67% to $230.1 million in 2022, then grew by 7.86% to $248.2 million in 2023, then increased by 1.07% to $250.9 million in 2024, then decreased by 5.68% to $236.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Gross PP&E Adjustments were $236.6 million in Q4 2025, $221.5 million in Q3 2025, and $232.8 million in Q2 2025.